[1] |
Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma[J]. Curr Dermatol Rep, 2013, 2(1):24-34.
|
[2] |
Bandarchi B, Ma L, Navab R, et al. From melanocyte to metastatic malignant melanoma[J]. Dermatol Res Pract, 2010, 2010:583748.
|
[3] |
Baniak N, Podberezin M, Kanthan SC, et al. Primary pulmonary/pleural melanoma in a 13 year-old presenting as pleural effusion[J]. Pathol Res Pract, 2017, 213(2):161-164.
doi: S0344-0338(16)30352-1
pmid: 27894618
|
[4] |
Kozovska Z, Gabrisova V, Kucerova L. Malignant melanoma: diagnosis, treatment and cancer stem cells[J]. Neoplasma, 2016, 63(4):510-517.
doi: 10.4149/neo_2016_403
pmid: 27268913
|
[5] |
Chhabra A, Mukherjee V, Chowdhary M, et al. Black pleural effusion: a unique presentation of metastatic melanoma[J]. Case Rep Oncol, 2015, 8(2):222-225.
doi: 10.1159/000430907
URL
|
[6] |
Saraya T, Light RW, Takizawa H, et al. Black pleural effusion[J]. Am J Med, 2013, 126(7):641,e1-e6.
|
[7] |
Dermawan JKT, Underwood D, Policarpio-Nicolas ML. Utility of sry-related HMG-box gene 10(SOX10) as a marker of melanoma in effusion cytology[J]. Diagn Cytopathol, 2019, 47(7):653-658.
doi: 10.1002/dc.24162
URL
|
[8] |
Sakaizawa K, Ashida A, Uhara H, et al. Detection of BRAF V600K mutant tumor-derived DNA in the pleural effusion from a patient with metastatic melanoma[J]. Clin Chem Lab Med, 2017, 55(4):e92-e95.
|
[9] |
Trinh VA. Current management of metastatic melanoma[J]. Am J Health Syst Pharm, 2008, 65(24 Suppl 9):S3-S8.
|
[10] |
Saade A, Mansuet-Lupo A, Arrondeau J, et al. Pericardial effusion under nivolumab: Case-reports and review of the literature[J]. J Immunother Cancer, 2019, 7(1):335.
doi: 10.1186/s40425-019-0822-7
URL
|
[11] |
Muñoz-Couselo E, García JS, Pérez-García JM, et al. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors[J]. Ann Transl Med, 2015, 3(15):207.
doi: 10.3978/j.issn.2305-5839.2015.05.13
pmid: 26488003
|